Visit the Canopy Growth Corp Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
SMITHS FALLS, ON and MONTREAL, May 28, 2018 /CNW/ – Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED, NYSE: CGC) is pleased to announce that Dr. Mark Ware, a leading researcher in the cannabis field for decades, will join the senior leadership team at Canopy Growth as the Company’s Chief Medical Officer commencing July 1st, 2018.
Dr. Ware is an associate professor of family medicine and anesthesia at McGill University. Over a period of 20 years he has established himself as a dedicated researcher and thought leader in advancing the medical community’s understanding of cannabis and cannabinoids. His research has focused on the safety, efficacy and effectiveness of cannabis and cannabinoids in pain and symptom management, and dates back well before the days of commercial cannabis production. He served for ten years as Executive Director of the non-profit Canadian Consortium for the Investigation of Cannabinoids (CCIC), and is also a longstanding Board Member of the International Association for Cannabinoid Medicines. In 2016, Dr. Ware served as vice-chair of the Government of Canada’s Task Force on Cannabis Legalization and Regulation. Dr Ware will take a leave of absence from McGill University to pursue this opportunity.
Bringing Dr. Mark Ware into a senior position within Canopy Growth demonstrates our commitment to building a well-funded, carefully refined global clinical research plan to develop new evidence, markets and products as it related to cannabis.
Bruce Linton, Chairman & CEO, Canopy Growth
His knowledge and expertise strengthen our ability to research and develop sophisticated cannabis medicines capable of improving patients’ lives around the world, while providing further clinical evidence as healthcare practitioners and governments are calling for.
In his role as Chief Medical Officer, Dr. Ware will lead Canopy Growth’s global clinical research strategy, while also assisting in medical education and all aspects of ensuring the Company builds a world-class medical division centered around its global medical business, Spectrum Cannabis.
I am very excited about the opportunity to join Canopy and to further develop global cannabis research. This approach is needed to more effectively respond to the needs of patients and health care professionals worldwide.
Dr. Mark Ware, Chief Medical Officer
The appointment of Dr. Ware follows on the heels of Canopy Growth’s announcement that it intends to acquire all outstanding shares in its affiliated cannabis research arm, Canopy Health Innovations Inc., including ownership in the recently established Oxford-based Beckley Canopy Therapeutics, a partnership with the renowned Beckley Foundation. Through strong research, drug development and clinical capabilities, along with a growing IP portfolio and top-tier management, Canopy is committed to a successful global medical cannabis industry.
Here’s to Future Growth (and welcome, Dr. Mark Ware!).
About Spectrum Cannabis
Spectrum is medical cannabis, simplified. Its colour-coded strain classification system is available in Canada with operations underway in the European Union and South America. Spectrum products are available in a range of potencies and formats designed to simplify the dialogue around strength and dosage by categorizing medical cannabis according to THC and CBD levels. Spektrum Germany Gmbh processes cannabis for sale in Germany in a GMP-certified facility and then distributes products to hundreds of German pharmacies. Spectrum Denmark is a partnership between Canopy Growth and Danish Cannabis. Through the partnership, Spectrum Denmark is developing a large-scale greenhouse facility in the city of Odense.
About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.
Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 2.4 million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The Company has operations in eight countries across four continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and through its partly owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. For more information visit www.canopygrowth.com
For fact-based information on Canopy Growth Corp, view the company’s sponsored Investor Dashboard.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.